Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific Antibody-Drug, Conjugate in Participants With Select Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT07612189 is registered in ClinicalTrials.gov with NEOK Bio, Inc. as lead sponsor.

NCT NCT07612189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific Antibody-Drug, Conjugate in Participants With Select Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
Lead sponsor
NEOK Bio, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 22, 2026
Completion date
February 28, 2029
Enrollment
155 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced (unresectable) or metastatic solid tumors